Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors



Status:Recruiting
Conditions:Lung Cancer, Colorectal Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Bladder Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/5/2018
Start Date:September 2016
End Date:January 2020
Contact:Incyte Corporation Call Center (US)
Email:medinfo@incyte.com
Phone:1.855.463.3463

Use our guide to learn which trials are right for you!

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in
combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

This study is an open-label Phase 1 evaluation of INCB001158 as a single agent and in
combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.

Single Agent INCB001158:

Patients with advanced/metastatic solid tumors will be enrolled into escalating monotherapy
dose cohorts to determine the Recommended Phase 2 Dose (RP2D) of INCB001158. Additional
patients with NSCLC, Colorectal Cancer (CRC), and other tumors including SCCHN, RCC, Gastric,
Bladder and Melanoma will be enrolled at the single agent RP2D.

Combination Treatment:

Patients with advanced/metastatic NSCLC, Melanoma, Urothelial, Microsatellite Instability
(MSI)/ Microsatellite Stable (MSS) CRC, Gastric, SCCHN and Mesothelioma will be enrolled into
separate cohorts of combination therapy (INCB001158 and Pembrolizumab) to determine the RP2D.

In the dose expansion phase, additional patients with NSCLC, Melanoma, Urothelial, MSI/MSS
CRC, Gastric, SCCHN and Mesothelioma will be treated with the combination of INCB001158 and
Pembrolizumab at the RP2D.

All patients will be assessed for safety, pharmacokinetics, biomarkers and tumor response.

*Additional cohort specific criteria may apply

Inclusion Criteria:

- Must be age 18 or older

- Ability to provide written informed consent in accordance with federal, local, and
institutional guidelines

- Histological or cytological diagnosis of metastatic cancer or locally advanced cancer
that is not amenable to local therapy

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1

- Life Expectancy of at least 3 months

- Adequate hepatic, renal, cardiac, and hematologic function

- Measurable disease by RECISTv1.1 criteria

- Resolution of treatment-related toxicities

- Willingness to avoid pregnancy or fathering children

- Prior anti-PD-1 treatment for combination dose expansion cohorts 3a - 3d

Exclusion Criteria:

- Currently pregnant or lactating

- Unable to receive oral medications

- Unable to receive oral or IV hydration

- Intolerance to prior anti-PD-1/PD-L1 therapy

- Prior anti-PD-1 treatment for combination dose expansion cohorts 3e - 3h

- Prior severe hypersensitivity reaction to another monoclonal antibody (mAb)

- Any other current or previous malignancy within 3 years except protocol allowed
malignancies

- Chemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy
within 2 weeks

- Immunotherapy or biological therapy, or investigational agent within 3 weeks (Note:
some cohort exceptions allow anti-PD-1 therapy)

- Active known or suspected exclusionary autoimmune disease

- Any condition requiring systemic treatment with either corticosteroids (> 10 mg daily
prednisone equivalent) or other systemic immunosuppressive medications within 2 weeks

- Concomitant therapy with valproic acid/valproate-containing therapies

- Concomitant therapy with allopurinol and other xanthine oxidase inhibitors

- History of known risks factors for bowel perforation

- Symptomatic ascites or pleural effusion

- Major surgery within 28 days before Cycle 1 Day 1

- Active infection requiring within 2 weeks prior to first dose of study drug

- Patients who have HIV, Hepatitis B or C

- Conditions that could interfere with treatment or protocol-related procedures

- Active, non-stable brain metastases or CNS disease

- Known deficiencies or suspected defect in the urea cycle

- Received live-virus vaccination within 30 days (seasonal flu vaccine allowed if
non-live virus)

- NSCLC with EGFR or ALK mutation
We found this trial at
12
sites
Boston, Massachusetts 02215
?
mi
from
Boston, MA
Click here to add this to my saved trials
Baltimore, Maryland 21218
(410) 516-8000
Johns Hopkins The Johns Hopkins University opened in 1876, with the inauguration of its first...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts 02115
?
mi
from
Boston, MA
Click here to add this to my saved trials
Detroit, Michigan 48202
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Aung Naing, MD
?
mi
from
Houston, TX
Click here to add this to my saved trials
307 N University Blvd
Mobile, Alabama 36688
(251) 460-6101
University of South Alabama "University of South Alabama is a public institution that was founded...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Nashville, Tennessee 37203
Principal Investigator: Todd Bauer, MD
?
mi
from
Nashville, TN
Click here to add this to my saved trials
Nashville, Tennessee 37212
?
mi
from
Nashville, TN
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Scottsdale, Arizona 85258
Principal Investigator: Frank Tsai, MD
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Tucson, Arizona 85721
(520) 621-2211
University of Arizona The University of Arizona is a premier, public research university. Established in...
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Washington, District of Columbia 02007
?
mi
from
Washington,
Click here to add this to my saved trials